Alkem Laboratories Limited has informed the Exchange about Outcome of Board Meeting held on 13th February, 2026
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Labs' board, meeting on 13 February 2026, approved standalone and consolidated unaudited results for Q3 and nine months ended 31 December 2025. Consolidated revenue from operations for Q3 stood at Rs. 37,368.2 million, up from Rs. 33,742.8 million in the same quarter last year. Net profit for Q3 was Rs. 6,530.3 million versus Rs. 6,407.9 million a year earlier, with nine-month profit at Rs. 21,000.5 million. The board declared an interim dividend of Rs. 43 per share (2150% on face value of Rs. 2), with record date 20 February 2026 and payment from 6 March 2026. The company also booked a Rs. 527.9 million exceptional charge in Q3 related to the new Labour Codes notified in November 2025.
Steady revenue and profit growth with continued dividend payouts should support shareholder confidence; however, the Labour Code-related exceptional charge is a one-time drag on Q3 earnings.